Novel treatments and guideline updates are frequent occurrences in many common blood malignancies in the United States. Review the latest breakthroughs involving treatment guidelines, real-world toxicities, prognostic indicators, and outcomes research in chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML).READ MORE
Despite significant treatment advancements in the management of multiple myeloma over the last 20 years, racial disparities in health care access and survival continue to exist.
In a recent study, researchers evaluated the role of autologous stem cell transplantation in patients with multiple myeloma in the context of novel agents.
Palliative care utilization among patients with hematologic malignancies remains extremely low.
Heart failure, angina, and other cardiovascular adverse events occur more frequently in patients with relapsed multiple myeloma receiving a conventional therapy.
Research in Review
A letter published in BMJ has raised concerns about the tendency for medical reviewers at the FDA to later transition into industry positions.
The American Society of Clinical Oncology released a clinical practice guideline update on the role of bone-modifying agents in patients with active symptomatic multiple myeloma.
From December 9-12, 2017, the American Society of Hematology hosted its Annual Meeting and Exposition in Atlanta, Georgia. The meeting provided an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology as well as to network with top minds in the field.